RxDoctor Payments Data

Michelle Peartree, PA

Medical · Fountain Hill, PANPI 1568429041

Payments from drug & device makers

$873in general payments, 2019–2025

Across 17 payments — averaging $51.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$302
  • Beigene USA, Inc.$198
  • Pharmacyclics LLC, An Abbvie Company$118
  • Seagen Inc.$85
  • Astellas Pharma US Inc$58
  • E.r. Squibb & Sons, L.L.C.$33
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$53661%
  • Education$33739%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$873 in reported general payments places this provider in the 65th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$35,180
Medicare patients
254
Services billed
434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide25$255,067
RevlimidLenalidomide13$234,695
ImbruvicaIbrutinib12$185,395
BrukinsaZanubrutinib11$154,165
NinlaroIxazomib Citrate11$144,791
CalquenceAcalabrutinib Maleate13$112,407
Abiraterone Acetate21$53,566
EliquisApixaban30$24,777
XareltoRivaroxaban31$23,920
Exemestane28$2,803
Anastrozole43$1,296
Prednisone76$765
Hydroxyurea19$592
Acyclovir21$181
Ondansetron Hcl15$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$118$185,39512 claims
Beigene USA, Inc.Brukinsa$198$154,16511 claims
AstraZenecaCalquence$302$112,40713 claims
PfizerEliquis$17$24,77730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Fountain Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →